{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-004187","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.287307+00:00","generated_at":"2026-06-17T21:27:17.065694+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Ra Medical stockholders approve issuance of >19.99% of common stock on warrants and units","bullets":["Proposal 1 approved: issuance of >19.99% of common stock upon exercise of Series E warrants; 259,937 for, 77,670 against.","Proposal 2 approved: issuance of >19.99% of common stock on Class A/B units and Series F/G warrants; 262,554 for.","Proposal 3 approved: issuance of common stock on conversion of Series X preferred (Catheter Precision merger); 268,043 for.","Proposal 4 ratified: Haskell & White LLP as auditor for FY2022; 1,248,217 for, 29,547 against.","All proposals passed; broker non-votes of 960,122 on proposals 1-3."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-004187","json":"https://secwatch.observer/filing/0001564590-23-004187.json","markdown":"https://secwatch.observer/filing/0001564590-23-004187.md","text":"https://secwatch.observer/filing/0001564590-23-004187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/rmed-8k_20230321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:27:17.065694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39f73ff16ad7d1f7bfc027c2a63de7dd428f2901","claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of common stock upon conversion of Series X Preferred Stock at the 2023-03-21 meeting.","evidence_excerpt":"3. Proposal No. 3: Approval, in Accordance with NYSE American Company Guide Section 712(b), the Issuance of Shares of Company Common Stock upon Conversion of Outstanding Series X Preferred Stock. In accordance with NYSE American Company Guide Section 712(b), the issuance of the Common Stock upon conversion of the Company’s Series X Convertible Preferred Stock, par value $0.0001 per share, which shares of Series X Convertible Preferred Stock were issued upon the closing of the merger between the Company and Catheter Precision, Inc., was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 268,043 70,714 6,088 960,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-21"}],"fact_type":"shareholder_vote"},{"claim_id":"4b1a689ae82392e93d7c2a0d0490d201afe6ec26","claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of outstanding common stock upon exercise of Series E warrants at the 2023-03-21 meeting.","evidence_excerpt":"1. Proposal No. 1: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding common stock, par value $0.0001 per share upon the exercise of our Series E Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 259,937 77,670 7,238 960,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-21"}],"fact_type":"shareholder_vote"},{"claim_id":"6f411ad3f78025245670c7e06495de393b038aa0","claim":"Catheter Precision, Inc. shareholders approved Approval of adjournment of Special Meeting at the 2023-03-21 meeting.","evidence_excerpt":"5. Proposal No. 5: Approval of the Adjournment of the Special Meeting. The approval of the adjournment of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3 and 4 was approved based on the following results of voting, although no such adjournment was required as a result of Proposal Nos. 1, 2, 3 and 4 being approved: Votes For Votes Against Abstentions Broker Non-Votes 1,181,196 87,075 36,696 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-21"}],"fact_type":"shareholder_vote"},{"claim_id":"7174b00766ae3716a78f1205064693ec3d2514d6","claim":"Catheter Precision, Inc. shareholders approved Ratification of independent registered public accounting firm Haskell & White LLP at the 2023-03-21 meeting.","evidence_excerpt":"4. Proposal No. 4: Ratification of Auditors. The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,248,217 29,547 27,203 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-21"}],"fact_type":"shareholder_vote"},{"claim_id":"854584aa03cf70ceb89a58d5ac1bbe3f7491734a","claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of common stock in connection with sale of Class A and B units and upon exercise of Series F and G warrants and conversion of Series A Preferred at the 2023-03-21 meeting.","evidence_excerpt":"2. Proposal No. 2: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding Common Stock (a) in connection with our sale of Class A units, which contain shares of common stock and Series F and G Common Stock Purchase Warrants, and Class B units, which contain shares of Series A Convertible Preferred Stock and Series F and G Common Stock Purchase Warrants, and (b) upon the exercise of the Series F and G Common Stock Purchase Warrants and the conversion of Series A Convertible Preferred Stock, with the right for such potential exercise or conversion to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 262,554 75,678 6,613 960,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-21"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}